Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Sanofi Takes On Infringing Look-Alike In India

Sanofi has sought to block an alleged infringer's attempt to ride on its trademarks, trade name and logo in India; the French multinational views these activities as intended to cause confusion among consumers.

Trademarks India Companies
Advertisement

Market Access

Set Alert for Market Access

Latest From Market Access

Ipsen CEO: 'I Assume a Hard Brexit', But Remain Bullish On UK Life Sciences

Ipsen's David Meek tells Scrip a Hard Brexit looks likely and that he's preparing the French pharma for that scenario.

Brexit Business Strategies

Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology

Roche used its ASCO investor briefing to highlight its digital and personalized healthcare strategy, including examples of how it’s facilitating R&D and reimbursement – and how that should position it to be an oncology leader in the future. 

Digital Health ASCO

Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose

Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.

Approvals Pricing Strategies

ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price

Amgen said when Aimovig was approved that its $6,900 list price was designed to make sure a lot of patients could access the migraine prophylaxis. ICER now says that's a reasonable price, assuming a $5,000 net cost for the CGRP inhibitor, but only for patients who have failed on other treatments.

Comparative Effectiveness Pricing Strategies

More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE

Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.

Rare Diseases Health Technology Assessment

Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence

Several biologic drugs are now available for the 10% of asthma patients with severe uncontrolled disease, and Dupixent could join them later this year, setting the therapy area up for a competitive showdown.

Respiratory Market Access
See All
UsernamePublicRestriction

Register